Victory Capital Management Inc. Sells 8,513 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. lowered its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 10.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,815 shares of the company's stock after selling 8,513 shares during the quarter. Victory Capital Management Inc. owned approximately 0.25% of Krystal Biotech worth $13,129,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Bancorp grew its stake in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Krystal Biotech in the 4th quarter valued at $95,000. Covestor Ltd boosted its position in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after buying an additional 642 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after buying an additional 432 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Krystal Biotech during the first quarter worth $223,000. 86.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. Citigroup restated a "neutral" rating and issued a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. HC Wainwright reiterated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, June 24th. Bank of America reduced their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $211.33.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $3.25 during trading hours on Thursday, hitting $150.00. The company's stock had a trading volume of 185,298 shares, compared to its average volume of 278,901. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34. The company has a market capitalization of $4.34 billion, a PE ratio of 36.06 and a beta of 0.67. The stock has a 50 day moving average of $137.92 and a 200 day moving average of $155.77.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Equities analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the sale, the insider owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 49,800 shares of company stock worth $7,487,943 over the last ninety days. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).